Developer docs
API playgroundTry for free, no card

Search company profiles

VIVEbiotech

Full company profile

uuid00027kg

Namestring
VIVEbiotech
Legal namestring
VIVEBIOTECH S.L.
Websiteurl
vivebiotech.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in San Sebastian, Spain, specializing exclusively in lentiviral vector development and manufacturing for gene and cell therapy applications. The company operates a 3,000 sq.m. state-of-the-art GMP-compliant manufacturing facility with seven dedicated cleanrooms and bioreactor production capacity ranging from 4 to 200 m2 (with 600 m2 expansion planned). Its proprietary technology platform encompasses stable producer cell line generation, custom lentiviral vector development with clonal activities and pseudotyping strategies, upstream and downstream process optimization, and the newly launched EvoLVcell platform for scalable production. The company holds GMP certification since 2017 and operates under both EMA and FDA regulatory standards, with in-house Qualified Person oversight for lot release.

The company's service portfolio covers the full development lifecycle: early-phase process development, R&D manufacturing, engineering and GMP lot production, fill/finish operations, analytical testing and release, stability studies, and regulatory documentation support for IMPD and IND submissions. VIVEbiotech serves both ex vivo (cell therapy, including CAR-T and TCR-NK) and in vivo (gene therapy) administration routes. Its customer base spans 60+ biotech and pharmaceutical companies globally across the US, Europe, Asia, and Australia, including named enterprise clients such as Galápagos, Xyphos (Astellas), Theravectys, and Zelluna Immunotherapy. The team of 130-140+ employees includes more than 85% advanced degree holders with 30+ years of combined virology experience.

VIVEbiotech generates revenue through project-based CDMO contracts priced by development stage, production scale, vector type, and service scope. The company employs a direct B2B enterprise sales model supported by active participation in major industry conferences (BIO International, ASGCT, ESGCT) and scientific publications. In December 2024, VIVEbiotech secured a growth equity investment from Ampersand Capital Partners (a healthcare-focused PE firm with over $3B AUM) to scale manufacturing capacity, with Dr. Stefan Beyer, former CEO of Vibalogics, appointed as Chairman. The company has manufactured over 200 batches in bioreactors and currently has 10+ in vivo lentiviral vector programs, several already in clinical phase, signaling expansion into higher-value gene therapy segments.

Short descriptiontext

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 in San Sebastian, Spain, exclusively specialized in lentiviral vector development and manufacturing for gene and cell therapy developers globally. The company operates a 3,000 sq.m. facility with seven cleanrooms, serving 60+ biotech and pharma clients across ex vivo and in vivo applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Sebastian, Spain
HQ citystring
San Sebastian
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lentiviral vector manufacturing, GMP CDMO services, cell therapy manufacturing, gene therapy CDMO, viral vector development
Industry3 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cell and Gene Therapy CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1GMP CDMO Manufacturing Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization providing process development, manufacturing and analytical testing for lentiviral vectors. Services include technology transfer, process development and optimization, R&D manufacturing in bioreactors, engineering lots, GMP lots, fill/finish, stability studies, and regulatory support (IMPD/IND). Revenue generated through project-based contracts with biotech and pharma companies developing gene and cell therapies.

vivebiotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based CDMO pricing based on service scope
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on development stage (early phase, preclinical, clinical phases I-III, commercial), production scale (4, 8, 10, 30, 200 m2, with 600 m2 upcoming), vector type (ex vivo vs in vivo), and specific service requirements (process development, GMP manufacturing, analytical testing, regulatory support).

vivebiotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) that develops and manufactures clinical and commercial-grade lentiviral vectors for gene and cell therapy applications. Services span custom vector development, upstream and downstream process development, GMP manufacturing across multiple bioreactor scales, analytical testing and release, regulatory support for IMPD/IND submissions, and stability studies for both ex vivo and in vivo administration routes. The company serves biotech and pharmaceutical clients globally from its 3,000 m² GMP facility in San Sebastian, Spain.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 200 batches manufactured in bioreactor with capacity for 60+ batches per year
+3 more records
Product overview1 text field

VIVEbiotech is a GMP CDMO specializing exclusively in lentiviral vector development and manufacturing for gene and cell therapy applications. The company operates as a single-focus CDMO providing end-to-end services from early-phase development through commercial supply. Their integrated service portfolio encompasses Custom Lentiviral Vector Development, Upstream Process Development (USP), Downstream Process Development (DSP), GMP Manufacturing, Analytical Testing & Release, Regulatory Support Services (IMPD/IND), and Stability Studies. Services are available for both ex vivo (cell therapy) and in vivo (gene therapy) administration routes. The company operates 7 dedicated cleanrooms in a 3,000 m² GMP facility in San Sebastian, Spain.

Product and service8 records
1Lentiviral Vector GMP Manufacturing (CDMO Services)
CategoryCDMO Manufacturing Services
Description

Contract Development and Manufacturing Organization (CDMO) services for GMP-grade lentiviral vectors for both ex vivo and in vivo gene and cell therapy applications. Includes process development, manufacturing across multiple bioreactor scales (4, 8, 10, 30, 200 m², with 600 m² upcoming), analytical testing, and regulatory support. Targeted at biotech and pharmaceutical companies developing gene and cell therapies.

2Custom Lentiviral Vector Development
CategoryCustom Vector Development
Description

Custom vector development services including producer cell line work, genetic modification for productivity and tropism, clonal activities from design to clonings for regulatory compliance, pseudotyping strategies, and transgene engineering for large-size genetic cargo. Targets gene and cell therapy developers needing tailored vector configurations.

3Upstream Process Development (USP)
CategoryProcess Development Services
Description

Upstream process development services covering cell expansion, bioreactor seeding conditions, transfection optimization, harvest conditions, and in-process controls to maximize productivity during lentiviral vector manufacturing. Targets CDMO clients requiring scalable, regulatory-compliant upstream workflows.

4Downstream Process Development (DSP)
CategoryProcess Development Services
Description

Downstream purification process optimization including chromatographic methods, tangential flow filtration (TFF), and fill and finish operations to maximize yield and product quality of lentiviral vectors. Targets CDMO clients requiring scalable, regulatory-compliant downstream workflows.

5GMP Analytical Testing & Release
CategoryAnalytical and Quality Services
Description

Quality control and analytical testing services for product release, including physicochemical, biochemical, molecular, and cell-based assays, with lot release by in-house Qualified Person. Targeted at CDMO clients requiring GMP-compliant analytical characterization of lentiviral vector products.

6Regulatory Support Services
CategoryRegulatory Services
Description

CMC documentation support for IMPD and IND submissions, including regulatory strategy, technical writing, and compliance with EMA and FDA requirements. Targeted at gene and cell therapy developers preparing clinical trial applications.

7Stability Studies
CategoryAnalytical and Quality Services
Description

Long-term and in-use stability studies for lentiviral vector products to support clinical and commercial shelf-life determination under defined storage conditions. Targeted at CDMO clients requiring regulatory-grade stability data for submissions.

8EvoLVcell Platform
CategoryManufacturing Platform Technology
Description

Technology platform for enhanced lentiviral vector production efficiency and scale-up. Targets CDMO clients requiring high-yield, scalable manufacturing of lentiviral vectors using stable producer cell line technology.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Long-standing partnership since 2018 for GMP manufacture of lentiviral vectors supporting TCR-NK therapy development targeting solid tumors. VIVEbiotech supports Zelluna's lead program ZI-MA4-1, the world's first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026. Partnership exemplifies VIVEbiotech's commitment to enabling next-generation cell therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hamburg-based CDMO specializing in viral vectors (including lentiviral) for cell and gene therapy. VIVEbiotech's chairman Dr. Stefan Beyer previously served as CEO/President of Vibalogics (acquired by Recipharm in 2022), making it a closely comparable direct peer in the LVV CDMO niche.

2Yposkesi (SK Pharmteco)
TypeDirect peer
Description

French viral vector CDMO focused on gene and cell therapy manufacturing, now part of SK Pharmteco. Directly comparable to VIVEbiotech as a specialized viral vector CDMO serving similar gene and cell therapy developers.

3Cobra Biologics (Charles River Laboratories)
TypeDirect peer
Description

UK-based viral vector and plasmid DNA CDMO acquired by Charles River Laboratories. Directly comparable as a contract manufacturer of lentiviral vectors and plasmids for gene and cell therapy clinical and commercial supply.

TypeDirect peer
Description

German manufacturer of viral vectors including lentiviral vectors derived from its proprietary packaging cell line technology. Directly comparable as a specialized viral vector CDMO for cell and gene therapy applications.

TypeEmerging player
Description

US-based viral vector CDMO focused on lentiviral and AAV manufacturing for gene therapy developers. Comparable to VIVEbiotech as an emerging specialized LVV manufacturer scaling capacity for clinical and commercial supply.

TypeBroad incumbent
Description

Large global CDMO offering cell and gene therapy services including lentiviral vector manufacturing as part of a broader biologics portfolio. Comparable as a multi-modality incumbent competing in the LVV CDMO market; VIVEbiotech board member Patricio Massera previously held leadership roles at AGC.

TypeBroad incumbent
Description

Major global CDMO with significant cell therapy and viral vector manufacturing capabilities. Provides lentiviral-related services at scale and competes with VIVEbiotech for cell and gene therapy clients seeking broader-service CDMOs.

TypeBroad incumbent
Description

One of the largest global CDMOs offering cell and gene therapy services including viral vector manufacturing. Represents a broad incumbent competitor that VIVEbiotech differentiates against through its exclusive LVV specialization.

TypeBroad incumbent
Description

Global CDMO arm of WuXi AppTec providing viral vector and cell therapy manufacturing including lentiviral vectors at scale. Competes with VIVEbiotech across geographies (notably Asia) with a broader service portfolio.

TypeOthers
Description

Supplier of upstream transfection reagents and plasmids critical to lentiviral vector manufacturing, now part of Sartorius. Comparable as an ecosystem enabler for LVV CDMOs rather than a direct competitor, but its adoption shapes the cost structure of LVV production.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VIVEbiotech

Cell and Gene Therapy CDMO Servicesvivebiotech.com

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 in San Sebastian, Spain, exclusively specialized in lentiviral vector development and manufacturing for gene and cell therapy developers globally. The company operates a 3,000 sq.m. facility with seven cleanrooms, serving 60+ biotech and pharma clients across ex vivo and in vivo applications.

What VIVEbiotech does

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in San Sebastian, Spain, specializing exclusively in lentiviral vector development and manufacturing for gene and cell therapy applications. The company operates a 3,000 sq.m. state-of-the-art GMP-compliant manufacturing facility with seven dedicated cleanrooms and bioreactor production capacity ranging from 4 to 200 m2 (with 600 m2 expansion planned). Its proprietary technology platform encompasses stable producer cell line generation, custom lentiviral vector development with clonal activities and pseudotyping strategies, upstream and downstream process optimization, and the newly launched EvoLVcell platform for scalable production. The company holds GMP certification since 2017 and operates under both EMA and FDA regulatory standards, with in-house Qualified Person oversight for lot release.

The company's service portfolio covers the full development lifecycle: early-phase process development, R&D manufacturing, engineering and GMP lot production, fill/finish operations, analytical testing and release, stability studies, and regulatory documentation support for IMPD and IND submissions. VIVEbiotech serves both ex vivo (cell therapy, including CAR-T and TCR-NK) and in vivo (gene therapy) administration routes. Its customer base spans 60+ biotech and pharmaceutical companies globally across the US, Europe, Asia, and Australia, including named enterprise clients such as Galápagos, Xyphos (Astellas), Theravectys, and Zelluna Immunotherapy. The team of 130-140+ employees includes more than 85% advanced degree holders with 30+ years of combined virology experience.

VIVEbiotech generates revenue through project-based CDMO contracts priced by development stage, production scale, vector type, and service scope. The company employs a direct B2B enterprise sales model supported by active participation in major industry conferences (BIO International, ASGCT, ESGCT) and scientific publications. In December 2024, VIVEbiotech secured a growth equity investment from Ampersand Capital Partners (a healthcare-focused PE firm with over $3B AUM) to scale manufacturing capacity, with Dr. Stefan Beyer, former CEO of Vibalogics, appointed as Chairman. The company has manufactured over 200 batches in bioreactors and currently has 10+ in vivo lentiviral vector programs, several already in clinical phase, signaling expansion into higher-value gene therapy segments.

VIVEbiotech firmographics

Firmographics
Name
VIVEbiotech
Legal name
VIVEBIOTECH S.L.
Website
https://vivebiotech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) founded in 2015 in San Sebastian, Spain, exclusively specialized in lentiviral vector development and manufacturing for gene and cell therapy developers globally. The company operates a 3,000 sq.m. facility with seven cleanrooms, serving 60+ biotech and pharma clients across ex vivo and in vivo applications.
Ownership category
akta.pro rank

VIVEbiotech industry classification

Industry
Product category
Cell and Gene Therapy CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Lentiviral vector manufacturing
  • GMP CDMO services
  • Cell therapy manufacturing
  • Gene therapy CDMO
  • Viral vector development

Where VIVEbiotech is headquartered

Location

Headquarters

HQ city
San Sebastian
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

VIVEbiotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. GMP CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing process development, manufacturing and analytical testing for lentiviral vectors. Services include technology transfer, process development and optimization, R&D manufacturing in bioreactors, engineering lots, GMP lots, fill/finish, stability studies, and regulatory support (IMPD/IND). Revenue generated through project-based contracts with biotech and pharma companies developing gene and cell therapies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CDMO pricing based on service scope

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

VIVEbiotech product offering

Product offering

Core offering

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) that develops and manufactures clinical and commercial-grade lentiviral vectors for gene and cell therapy applications. Services span custom vector development, upstream and downstream process development, GMP manufacturing across multiple bioreactor scales, analytical testing and release, regulatory support for IMPD/IND submissions, and stability studies for both ex vivo and in vivo administration routes. The company serves biotech and pharmaceutical clients globally from its 3,000 m² GMP facility in San Sebastian, Spain.

Product overview

VIVEbiotech is a GMP CDMO specializing exclusively in lentiviral vector development and manufacturing for gene and cell therapy applications. The company operates as a single-focus CDMO providing end-to-end services from early-phase development through commercial supply. Their integrated service portfolio encompasses Custom Lentiviral Vector Development, Upstream Process Development (USP), Downstream Process Development (DSP), GMP Manufacturing, Analytical Testing & Release, Regulatory Support Services (IMPD/IND), and Stability Studies. Services are available for both ex vivo (cell therapy) and in vivo (gene therapy) administration routes. The company operates 7 dedicated cleanrooms in a 3,000 m² GMP facility in San Sebastian, Spain.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lentiviral Vector GMP Manufacturing (CDMO Services) Contract Development and Manufacturing Organization (CDMO) services for GMP-grade lentiviral vectors for both ex vivo and in vivo gene and cell therapy applications. Includes process development, manufacturing across multiple bioreactor scales (4, 8, 10, 30, 200 m², with 600 m² upcoming), analytical testing, and regulatory support. Targeted at biotech and pharmaceutical companies developing gene and cell therapies.
  • Custom Lentiviral Vector Development Custom vector development services including producer cell line work, genetic modification for productivity and tropism, clonal activities from design to clonings for regulatory compliance, pseudotyping strategies, and transgene engineering for large-size genetic cargo. Targets gene and cell therapy developers needing tailored vector configurations.
  • Upstream Process Development (USP) Upstream process development services covering cell expansion, bioreactor seeding conditions, transfection optimization, harvest conditions, and in-process controls to maximize productivity during lentiviral vector manufacturing. Targets CDMO clients requiring scalable, regulatory-compliant upstream workflows.
  • Downstream Process Development (DSP) Downstream purification process optimization including chromatographic methods, tangential flow filtration (TFF), and fill and finish operations to maximize yield and product quality of lentiviral vectors. Targets CDMO clients requiring scalable, regulatory-compliant downstream workflows.
  • GMP Analytical Testing & Release Quality control and analytical testing services for product release, including physicochemical, biochemical, molecular, and cell-based assays, with lot release by in-house Qualified Person. Targeted at CDMO clients requiring GMP-compliant analytical characterization of lentiviral vector products.
  • Regulatory Support Services CMC documentation support for IMPD and IND submissions, including regulatory strategy, technical writing, and compliance with EMA and FDA requirements. Targeted at gene and cell therapy developers preparing clinical trial applications.
  • Stability Studies Long-term and in-use stability studies for lentiviral vector products to support clinical and commercial shelf-life determination under defined storage conditions. Targeted at CDMO clients requiring regulatory-grade stability data for submissions.
  • EvoLVcell Platform Technology platform for enhanced lentiviral vector production efficiency and scale-up. Targets CDMO clients requiring high-yield, scalable manufacturing of lentiviral vectors using stable producer cell line technology.

Quantifiable outcome

  • Over 200 batches manufactured in bioreactor with capacity for 60+ batches per year
  • +3 more outcomes

Companies that use VIVEbiotech

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

VIVEbiotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

VIVEbiotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ZellunacoreStrategic or Co-development Partner · 1 January 2018Long-standing partnership since 2018 for GMP manufacture of lentiviral vectors supporting TCR-NK therapy development targeting solid tumors. VIVEbiotech supports Zelluna's lead program ZI-MA4-1, the world's first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026. Partnership exemplifies VIVEbiotech's commitment to enabling next-generation cell therapies.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

VIVEbiotech competitors and assessment

Company assessment

Direct peers

  • Vibalogics: Hamburg-based CDMO specializing in viral vectors (including lentiviral) for cell and gene therapy. VIVEbiotech's chairman Dr. Stefan Beyer previously served as CEO/President of Vibalogics (acquired by Recipharm in 2022), making it a closely comparable direct peer in the LVV CDMO niche.
  • Yposkesi (SK Pharmteco): French viral vector CDMO focused on gene and cell therapy manufacturing, now part of SK Pharmteco. Directly comparable to VIVEbiotech as a specialized viral vector CDMO serving similar gene and cell therapy developers.
  • Cobra Biologics (Charles River Laboratories): UK-based viral vector and plasmid DNA CDMO acquired by Charles River Laboratories. Directly comparable as a contract manufacturer of lentiviral vectors and plasmids for gene and cell therapy clinical and commercial supply.
  • Cevec Pharmaceuticals: German manufacturer of viral vectors including lentiviral vectors derived from its proprietary packaging cell line technology. Directly comparable as a specialized viral vector CDMO for cell and gene therapy applications.

Emerging players

  • Genezen: US-based viral vector CDMO focused on lentiviral and AAV manufacturing for gene therapy developers. Comparable to VIVEbiotech as an emerging specialized LVV manufacturer scaling capacity for clinical and commercial supply.

Broad incumbents

  • AGC Biologics: Large global CDMO offering cell and gene therapy services including lentiviral vector manufacturing as part of a broader biologics portfolio. Comparable as a multi-modality incumbent competing in the LVV CDMO market; VIVEbiotech board member Patricio Massera previously held leadership roles at AGC.
  • Catalent (Novo Holdings): Major global CDMO with significant cell therapy and viral vector manufacturing capabilities. Provides lentiviral-related services at scale and competes with VIVEbiotech for cell and gene therapy clients seeking broader-service CDMOs.
  • Lonza: One of the largest global CDMOs offering cell and gene therapy services including viral vector manufacturing. Represents a broad incumbent competitor that VIVEbiotech differentiates against through its exclusive LVV specialization.
  • WuXi Advanced Therapies (WuXi AppTec): Global CDMO arm of WuXi AppTec providing viral vector and cell therapy manufacturing including lentiviral vectors at scale. Competes with VIVEbiotech across geographies (notably Asia) with a broader service portfolio.

Others

  • Polyplus (Sartorius): Supplier of upstream transfection reagents and plasmids critical to lentiviral vector manufacturing, now part of Sartorius. Comparable as an ecosystem enabler for LVV CDMOs rather than a direct competitor, but its adoption shapes the cost structure of LVV production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

VIVEbiotech social profiles

Digital presence

VIVEbiotech compliance and trust

Trust signal

Compliance5 records

VIVEbiotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VIVEbiotech leadership team

Management profile

Number of profiles

Profiles11 records

VIVEbiotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VIVEbiotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VIVEbiotech

What does VIVEbiotech do?

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) that develops and manufactures clinical and commercial-grade lentiviral vectors for gene and cell therapy applications. Services span custom vector development, upstream and downstream process development, GMP manufacturing across multiple bioreactor scales, analytical testing and release, regulatory support for IMPD/IND submissions, and stability studies for both ex vivo and in vivo administration routes. The company serves biotech and pharmaceutical clients globally from its 3,000 m² GMP facility in San Sebastian, Spain.

Is VIVEbiotech a public or private company?

VIVEbiotech is a private company. It is classified as private equity controlled and is currently operating.

When was VIVEbiotech founded?

VIVEbiotech was founded in 2015. It employs 101 to 250 people.

Where is VIVEbiotech based?

VIVEbiotech is headquartered in San Sebastian, Spain, in the Europe region.

How does VIVEbiotech make money?

One revenue line is on record: GMP CDMO Manufacturing Services.

Who are VIVEbiotech's main competitors?

Direct peers on record are Vibalogics, Yposkesi (SK Pharmteco), Cobra Biologics (Charles River Laboratories) and Cevec Pharmaceuticals. Genezen is listed as an emerging player. Broad incumbents are AGC Biologics, Catalent (Novo Holdings), Lonza and WuXi Advanced Therapies (WuXi AppTec). Polyplus (Sartorius) is listed as an others.

Does VIVEbiotech have an API?

No public API is recorded for VIVEbiotech.

What industry is VIVEbiotech in?

VIVEbiotech's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsCAR T Manufacturing Innovation Expands Patient AccessIndustry leaders from VIVEbiotech, Terumo Blood and Cell Technologies, and Bracco are advancing CAR T therapy manufacturing through automation and process integration to address scalability and cost challenges. Experts emphasize that parallel development of ex vivo and in vivo approaches, combined with closed workflow systems, will improve product consistency and expand patient access. These innovations aim to transition the field from scientific feasibility to robust, commercially sustainable production.PharmiWeb.comPharmiWeb.com – Thank youPharmiWeb.com is closing after 28 years, having operated since 1998. The site helped people find opportunities and build careers across the industry. The company thanks members, advertisers, partners, and readers for their participation.GlobeNewswireVIVEbiotech Appoints Patricio Massera as PresidentVIVEbiotech appointed Patricio Massera as President, adding him to its Board of Directors. The appointment follows a growth investment from Ampersand Capital Partners and aims to scale operations and expand globally. Massera brings over 25 years of CDMO leadership experience, including as CEO of AGC Biologics.citybizVIVEbiotech Receives Investment from Ampersand Capital PartnersVIVEbiotech, a Spanish lentiviral vector CDMO, received a growth equity investment from Ampersand Capital Partners, with the amount undisclosed. Dr. Stefan Beyer was named chairman, and the funds will support lentiviral vector manufacturing and customer projects for gene and cell therapies.WebcapitalriesgoVIVEbiotech Obtiene una Inversión de Ampersand Capital Partners para Ampliar sus Capacidades de Desarrollo y Fabricación de Vectores LentiviralesVIVEbiotech announced an investment from Ampersand Capital Partners to expand its lentiviral vector manufacturing capacity in San Sebastián, Spain. The partnership will support client projects in gene and cell therapies, with Dr. Stefan Beyer named CEO. The company serves over 40 biotech firms.Empresas de Capital Riesgo en EspaVIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing CapabilitiesAmpersand Capital Partners invested in VIVEbiotech to expand its lentiviral vector manufacturing in Spain. The partnership will support a pipeline of customer projects for cell and gene therapies. Dr. Stefan Beyer was named chairman of VIVEbiotech.PharmiWeb.comVIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing CapabilitiesVIVEbiotech announced a growth equity investment from Ampersand Capital Partners to expand its lentiviral vector manufacturing in San Sebastian, Spain. The partnership will support its pipeline of customer projects for cell and gene therapies. Dr. Stefan Beyer was named chairman of VIVEbiotech.PR NewswireVIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing CapabilitiesVIVEbiotech announced a growth equity investment from Ampersand Capital Partners to expand its lentiviral vector manufacturing in San Sebastian, Spain. The partnership will support its pipeline of customer projects for cell and gene therapies. Dr. Stefan Beyer was named chairman of VIVEbiotech.Labiotech.euBeyond Biotech podcast 31: Orgenesis, Phacilitate, Terumo, University of Birmingham, VIVEBiotechA podcast episode features guests from Phacilitate, Orgenesis, Terumo, the University of Birmingham, and VIVEBiotech, discussing their advanced therapies businesses. Phacilitate's Advanced Therapies Week occurred in Miami Beach, and the guests represent companies in cell and gene therapies, medical technology, and lentiviral vectors.